INHIBITORS OF BACTERIAL RNA POLYMERASE: "SWITCH REGION"
INHIBITORS OF BACTERIAL RNA POLYMERASE: "SWITCH REGION"
批准号:
7337094
负责人:
RICHARD H. EBRIGHT
金额:
$58.81万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-01-01 至 2011-12-31
关键词:
AddressAffectAnti-Bacterial AgentsBacterial InfectionsBindingBiological FactorsBiological WarfareBioterrorismClinicalCloningComplexCrystallographyDNADNA-Directed RNA PolymeraseDevelopmentElementsEscherichia coliEvaluationExhibitsFutureGene ClusterGenetic TranscriptionGrowthLactonesMediatingMolecular CloningMolecular ConformationPolymerasePublic HealthPyronesRNA Polymerase IRNA Polymerase IIRNA Polymerase IIIReactionResearch PersonnelResistanceRifabutinRifampinScreening procedureStructureThermus thermophilusTranscription InitiationWorkbaseinhibitor/antagonistnovelprogramsrifapentinesingle moleculesingle-molecule FRETsmall moleculetool
中文摘要
初步工作确定了三种天然产物-聚酮衍生的a-吡喃酮粘焦宁,
多利酮衍生的α-吡喃酮珊瑚吡喃酮和聚酮衍生的大环内酯Ripostatin抑制剂
细菌RNA聚合酶(RNAP)通过与RNAP“开关区”(一种结构元件)的相互作用
介导RNAP结合并保留DMA模板所需的构象变化,
转录。所述化合物不抑制真核RNAP I、RNAP II或RNAP III。化合物
明显抑制革兰氏阳性菌和革兰氏阴性菌的生长,
目前临床上用于治疗细菌感染的细菌RNAP的抑制剂(抗细菌的泰利福霉素
药物,利福平,利福喷丁和利福贝汀),并且与其他细菌性大肠杆菌抑制剂不表现出交叉耐药性。
RNAP正在评估未来在细菌感染治疗中的临床应用。
这项工作将使用x射线晶体学,系综和单分子荧光共振
能量转移,单分子纳米操纵,分子克隆,替代宿主表达,
基于结构的筛选和从头筛选,以实现四个具体目标:
具体目的1:确定RNAP与转换区靶点抑制剂的复合物的结构
具体目的2:确定开关区靶点抑制剂抑制RNAP的机制
具体目标3:生物合成基因簇的克隆、表征和替代宿主表达
转换区靶点抑制剂
具体目标4:新型开关区靶点抑制剂的鉴定和表征
这些结果将有助于开发新的广谱抗菌剂,
对目前使用的抗菌剂具有抗性的细菌菌株。因此,其结果将直接
与公共卫生的相关性以及与针对可能
用于生物战或生物恐怖主义此外,研究结果将有助于理解RNAP结构
并将提供分析国家行动方案区域办事处结构和职能的工具。
英文摘要
Preliminary work establishes that three natural products-the polyketide-derived a-pyrone myxopyronin, the
Dolyketide-derived a-pyrone corallopyronin, and the polyketide-derived macrocylic lactone ripostatin-inhibit
Dacterial RNA polymerase (RNAP) through interactions with the RNAP "switch region," a structural element
that mediates conformational changes required for RNAP to bind and retain the DMAtemplate in
transcription. The compounds do not inhibit eukaryotic RNAP I, RNAP II, or RNAP III. The compounds
ootently inhibit Gram-positive and Gram-negative bacterial growth, exhibit no cross-resistance with the
nhibitors of bacterial RNAP in current clinical use in therapy of bacterial infection (therifamycin antibacterial
agents, rifampicin, rifapentine, and rifabutin), and exhibit no cross-resistance with other inhibitors of bacterial
RNAP under evaluation for future clinical use in therapy of bacterial infection.
The proposed work wilt use x-ray crystallography, ensemble and single-molecule fluorescence resonance
energy transfer, single-molecule nanomanipulation, molecular cloning, surrogate-host expression,
structure-based screening, and de novo screening, to address four specific aims:
Specific Aim 1: Determination of structures of complexes of RNAP with switch-region-target inhibitors
Specific Aim 2: Determination of mechanisms of inhibition of RNAP by switch-region-target inhibitors
Specific Aim 3: Cloning, characterization, and surrogate-host expression of biosynthetic gene clusters
for switch-region-target inhibitors
Specific Aim 4: Identification and characterization of novel switch-region-target inhibitors
The results will enable development of new broad-spectrum antibacterial agents that will be effective against
bacterial strains resistant to currently used antibacterial agents. As such, the results will have direct
relevance to public health and to development of countermeasures against bacterial strains that could be
used in biowarfare or bioterrorism. In addition, the results will contribute to understanding RNAP structure
and function and will provide tools for analysis of RNAP structure and function.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Bacterial Transcription Complexes
-
批准号:10388566
-
项目类别:
-
资助金额:$5.1万
-
财政年份:2021
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for drug-resistant bacteria: aryl myxopyronins and arylalkylcarboxamido phloroglucinols
-
批准号:10394990
-
项目类别:
-
资助金额:$65.16万
-
财政年份:2019
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for drug-resistant bacteria: aryl myxopyronins and arylalkylcarboxamido phloroglucinols
-
批准号:10613893
-
项目类别:
-
资助金额:$65.16万
-
财政年份:2019
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Pseudouridimycins
-
批准号:8978290
-
项目类别:
-
资助金额:$102.17万
-
财政年份:2013
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Pseudouridimycins
-
批准号:8603843
-
项目类别:
-
资助金额:$102.17万
-
财政年份:2013
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Pseudouridimycins
-
批准号:8782465
-
项目类别:
-
资助金额:$102.17万
-
财政年份:2013
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Pseudouridimycins
-
批准号:8474439
-
项目类别:
-
资助金额:$104.89万
-
财政年份:2013
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Myxopyronins
-
批准号:8476980
-
项目类别:
-
资助金额:$114.02万
-
财政年份:2010
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Myxopyronins
-
批准号:8288777
-
项目类别:
-
资助金额:$121.3万
-
财政年份:2010
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Myxopyronins
-
批准号:8105468
-
项目类别:
-
资助金额:$120.94万
-
财政年份:2010
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Myxopyronins
-
批准号:8697004
-
项目类别:
-
资助金额:$121.3万
-
财政年份:2010
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
Therapeutics for Drug-Resistant Bacteria: Myxopyronins
-
批准号:7989018
-
项目类别:
-
资助金额:$124.8万
-
财政年份:2010
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
BACTERIAL TRANSCRIPTION COMPLEXES
-
批准号:7932650
-
项目类别:
-
资助金额:$4.84万
-
财政年份:2009
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
INHIBITORS OF BACTERIAL RNA POLYMERASE: "SWITCH REGION"
-
批准号:7742240
-
项目类别:
-
资助金额:$58.22万
-
财政年份:2007
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
INHIBITORS OF BACTERIAL RNA POLYMERASE: "SWITCH REGION"
-
批准号:7187263
-
项目类别:
-
资助金额:$59.85万
-
财政年份:2007
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
INHIBITORS OF BACTERIAL RNA POLYMERASE: "SWITCH REGION"
-
批准号:7540990
-
项目类别:
-
资助金额:$58.81万
-
财政年份:2007
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
INHIBITORS OF BACTERIAL RNA POLYMERASE: "SWITCH REGION"
-
批准号:8009521
-
项目类别:
-
资助金额:$55.96万
-
财政年份:2007
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
EUKARYOTIC TRANSCRIPTION COMPLEXES
-
批准号:6046298
-
项目类别:
-
资助金额:$15.85万
-
财政年份:1996
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
EUKARYOTIC TRANSCRIPTION COMPLEXES
-
批准号:6363271
-
项目类别:
-
资助金额:$16.32万
-
财政年份:1996
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
EUKARYOTIC TRANSCRIPTION COMPLEXES
-
批准号:2668516
-
项目类别:
-
资助金额:$14.93万
-
财政年份:1996
-
负责人:RICHARD H. EBRIGHT
-
依托单位:
海外基金